Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Approval Status for Methadone Hydrochloride by ThePharmaNetwork LLC

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/29/2026, 12:32:11 PM

Assessment confidence: 53% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of Methadone Hydrochloride by ThePharmaNetwork LLC is a significant development in the opioid market, potentially enhancing their competitive position. Pharma strategy teams should closely monitor market dynamics and competitor responses to this approval. Regulatory context from FDA (FDA AP — METHADONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 14 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and pricing strategies for opioid products. The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 7 regulatory and 3 competitive items passed relevance filtering for Methadone Hydrochloride.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This approval may enhance ThePharmaNetwork LLC's position in the opioid market, potentially impacting competitors in pain management therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — METHADONE HYDROCHLORIDE (SUPPL) (FDA). Entity match (methadone hydrochloride); Regulatory pathway relevance (nda). The approval status indicates compliance with FDA regulations, but ongoing monitoring of market launch and regulatory developments is necessary.

Key Risks

Elevated medium regulatory exposure for Methadone Hydrochloride could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

This approval could lead to increased market share for ThePharmaNetwork LLC, impacting pricing strategies and competitive positioning among opioid products.
Portfolio teams should assess the implications of this approval on market share and pricing strategies for opioid products.

What Would Change This Assessment

This becomes more urgent if Monitor for further developments regarding market launch and any competitive responses from other opioid manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE INTENSOL (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
ClinicalTrials.govlow relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Grants Priority Review for TRYNGOLZA Autoinjector Submission
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Methadone Hydrochloride
pain management therapies

Commercial impact

medium

This approval could lead to increased market share for ThePharmaNetwork LLC, impacting pricing strategies and competitive positioning among opioid products.

Regulatory impact

medium

The approval status indicates compliance with FDA regulations, but ongoing monitoring of market launch and regulatory developments is necessary.

What to watch

Monitor for further developments regarding market launch and any competitive responses from other opioid manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.